Suchen
Femasys Inc
FEMYZur Watchlist hinzufügen
2.560USD
0.0000.00%
Trading geöffnet 09/23, 13:36（ET）
7.73MMarktkapitalisierung
VerlustKGV TTM
Über Femasys Inc Unternehmen
Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
Femasys Inc Profil
BörsenkürzelFEMY
Name des UnternehmensFemasys Inc
IPO-datumJun 18, 2021
CEOLee-Sepsick (Kathy)
Anzahl der mitarbeiter69
WertpapierartOrdinary Share
GeschäftsjahresendeJun 18
Addresse3950 Johns Creek Court
StadtSUWANEE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl30024
Telefon17705003910
Websitehttps://www.femasys.com/
BörsenkürzelFEMY
IPO-datumJun 18, 2021
CEOLee-Sepsick (Kathy)
Führungskräfte von Femasys Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Kathy Lee-Sepsick
Ms. Kathy Lee-Sepsick
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
37.27K
+41.93%
Ms. Kathy Lee-Sepsick
Ms. Kathy Lee-Sepsick
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
37.27K
+41.93%
Mr. John Canning
Mr. John Canning
Chief Operating Officer
Chief Operating Officer
5.88K
+74.47%
Mr. John Canning
Mr. John Canning
Chief Operating Officer
Chief Operating Officer
5.88K
+74.47%
Dr. Kenneth D. Eichenbaum, M.D.
Dr. Kenneth D. Eichenbaum, M.D.
Independent Director
Independent Director
1.25K
--
Dr. Kenneth D. Eichenbaum, M.D.
Dr. Kenneth D. Eichenbaum, M.D.
Independent Director
Independent Director
1.25K
--
Ms. Kelley Nicholas
Ms. Kelley Nicholas
Chief Commercial Officer
Chief Commercial Officer
4.00
--
Ms. Kelley Nicholas
Ms. Kelley Nicholas
Chief Commercial Officer
Chief Commercial Officer
4.00
--
Mr. Charles E. Larsen
Mr. Charles E. Larsen
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Edward Uzialko, Jr.
Mr. Edward Uzialko, Jr.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Kathy Lee-Sepsick
Ms. Kathy Lee-Sepsick
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
37.27K
+41.93%
Ms. Kathy Lee-Sepsick
Ms. Kathy Lee-Sepsick
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
37.27K
+41.93%
Mr. John Canning
Mr. John Canning
Chief Operating Officer
Chief Operating Officer
5.88K
+74.47%
Mr. John Canning
Mr. John Canning
Chief Operating Officer
Chief Operating Officer
5.88K
+74.47%
Dr. Kenneth D. Eichenbaum, M.D.
Dr. Kenneth D. Eichenbaum, M.D.
Independent Director
Independent Director
1.25K
--
Dr. Kenneth D. Eichenbaum, M.D.
Dr. Kenneth D. Eichenbaum, M.D.
Independent Director
Independent Director
1.25K
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Femasys Inc?
Die fünf größten Anteilseigner von Femasys Inc sind: Ms. Kathy Lee-Sepsick
Wie viele Institutionen halten Anteile an Femasys Inc (FEMY)?
Mit Stand vom 2026Q1 halten 64 Institutionen Anteile an Femasys Inc, mit einem Gesamtmarktwert von etwa 6.18M, was 10.23% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 1191594.00 gestiegen.